News

Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS…

Reducing Overall Mortality by Combining Three Antihypertensives into a Single Pill

What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?

Current European Recommendations for the Treatment of Renal Colic Due to Urolithiasis

MD Šimon Kozák: In algology, nothing works miraculously overnight! It is important to seek advice from specialists

Efficacy and Safety of Fenfluramine in the Treatment of Lennox-Gastaut Syndrome – An Overview of Current Knowledge

Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies

Hybrid Cooperating Complexes in Osteoarthritis Treatment

Possibilities of Cannabis Use in Tourette Syndrome Therapy

Bimekizumab in the Treatment of Psoriatic Arthritis
Conferences
News from the world of medicine
All conferences
Popular this week
- Intermittent Fasting May Carry Significant Health Risks
- Tuberous Sclerosis
- Multiple system atrophy
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- BENIGN DERMATOSIS OF PENIS